Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$2.48 ▼ -0.04
(-1.59%)
MKT CAP: $148.9M • VOL: 581.2K
52W L $2 52W H $8
ROARABLE / RQD
D- • 43/100
PIOTROSKI
2 / 9
TARA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$64.5M | -$49.2M | -$43.6M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$57.4M | -$44.6M | -$40.4M |
| EBITDA (Normalized) | -$64.5M | -$49.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$56.4M | -$35.8M | -$37.6M |
| Capital Expenditures (CapEx) | $94.0K | $63.0K | — |
| Free Cash Flow (FCF) | -$56.5M | -$35.9M | -$37.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -34.7% | -45.0% | — |
| Cash & Short-Term Equivalents | $49.7M | $162.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $196.4M | $167.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TARA.